Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase™ 2018

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer therapeutics, today announced that Jeff Behrens, president and chief executive officer, will present at the 10thannual Biotech Showcase™ conference in San Francisco on Tuesday, January 9, 2018 at 1:45 p.m. PT. The conference will be held January 8-10, 2018, at the Hilton San Francisco Union Square.

Mr. Behrens will provide an overview of the company, its proprietary technology platform and its development pipeline, including the ST1 program. ST1, Siamab’s lead monoclonal antibody (mAb) therapeutic, is in late stage preclinical development formatted as an antibody drug conjugate (ADC) for the treatment of solid tumors expressing Sialyl-Tn (STn). Mr. Behrens will also present new data on targeting STn+ myeloid-derived suppressor cells (MDSCs), major regulators of the tumor anti-immune response that act by suppressing T cells. Siamab has for the first time identified and utilized the presence of STn on MDSCs to target and deplete MDSCs in vivo, providing a potential new therapeutic approach for the treatment of solid tumors.